Lurasidone: A clinical overview

Journal of Clinical Psychiatry

Volumn 72, Issue SUPPL. 1, 2011, Pages 24-28

  Kane, John M ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DILTIAZEM; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LURASIDONE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

AKATHISIA; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BINDING; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOCRINE DISEASE; EVENING DOSAGE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OBESITY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84555190789     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10075su1.05     Document Type: Review

References (21)

1. Latuda [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; October 2010 http://www.latuda.com/ LatudaPrescribingInformation.pdf. Accessed June 15, 2011.
2. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-181. doi:10.124/jpet.10.167346 PubMed
3. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11(7):802-812. PubMed
4. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11):1715-1726. doi:10.1517/1354378090328638 PubMed
5. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011;338(2):605-614. PubMed
6. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4(4):251-257. doi:10.371/CSRP.4.4.5 PubMed
7. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189-210. doi:10.1/j.1742-1241.2010.02587.x PubMed
8. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7:239-250. doi:10.2147/TCRM.S12701 PubMed
9. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-836. doi:10.408/JCP.08m04905 PubMed
10. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957-967. doi:10.176/api.ajp.201.1060907 PubMed
11. Loebel A, Cucchiaro J, Sarma K, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, Pearl 3 trial. Presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011; Honolulu, HI.
12. Potkin SG, Ogasa M, Cucchiaro J, et al. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder [published online ahead of print September 1, 2011]. Schizophr Res.
13. Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs ziprasidone. Schizophr Res. 2011;127(1-3):188-194. doi:10.1016/j.schres.201.01.04 PubMed
14. Ishiyama T, Tokuda K, Ishibashi T, et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 2007;572(2-3):160- 170. doi:10.1016/j.ejphar.207.06.058 PubMed (Pubitemid 47429645)
15. Enomoto T, Ishibashi T, Tokuda K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res. 2008;186(2):197-207. doi:10.1016/j.br.207.08.012 PubMed (Pubitemid 350122756)
16. Harvey PD, Murasaki M, Cucchiaro J, et al. A three arm dose finding study of lurasidone: efficacy and tolerability data. Schizophr Res. 2010;117(2-3):374-375 [abstract]. doi:10.1016/j.schres.2010.02.69
17. Stahl SM, Cucchiaro J, Simonelli D, et al. Long-term safety and tolerability of lurasidone in patients with schizophrenia: results of a 6-month, openlabel extension study. Presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011; Honolulu, HI.
18. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia or schizoaffective disorder: a 12-month, double-blind, active-controlled study. Presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011; Honolulu, HI.
19. Pikalov A, Cucchiaro J, Ogasa M, et al. Effect of lurasidone on weight and metabolic parameters: results from pooled short-term placebo-controlled and longer-term extension trials in schizophrenia. Presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011; Honolulu, HI.
20. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4(3):229-237. doi:10.2174/1574860978906985 PubMed
21. Newcomer JW, Pikalov A, Cucchiaro J, et al. Impact of lurasidone and olanzapine on Framingham ten year coronary heart disease risk estimate in schizophrenia. Presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011; Honolulu, HI.